Figure 4.

NSCLC FUTCs predict genotype-matched therapeutic responses

(A) Dose-response curves of gefitinib, osimertinib, and AF in patient-matched tumor-derived EpCAM⁺ and EpCAM^– cells.

(B) DSS for gefitinib, osimertinib, and AF compared between EGFR mutant EpCAM⁺, EGFR wild-type EpCAM⁺, tumor EpCAM^–, and normal EpCAM⁺ cells. Each dot represents an independent sample.

(C and D) Bar graph representing the DSS of crizotinib (C) and (D) ceritinib and crizotinib across all of the patient samples.

(E) Dose-response curves of crizotinib in patient-matched tumor-derived EpCAM⁺ or normal tissue-derived EpCAM⁺ cells.

(F) Dose-response curves of ceritinib in patient-matched tumor-derived EpCAM⁺ and EpCAM^– cells.

(G) Representative IHC images of E-cadherin and vimentin staining in patient (PLT64)-derived EML4-ALK⁺ lung tumor tissues. Scale bars correspond to 200 or 20 μm for low or high magnifications, respectively. Boxes indicate areas shown in the higher magnification in a lower row.

Error bars represent ±SEMs. Two-tailed unpaired Student’s t test: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.